Haploinsufficiency of CDKN1B contributes to leukemogenesis in T-cell prolymphocytic leukemia

Blood

Volumn 111, Issue 4, 2008, Pages 2321-2328

  Le Toriellec, Emilie ^a,b   Despouy, Gilles ^a,b   Pierron, Gaëlle ^a,b   Gaye, Nogaye ^a,b   Joiner, Marjorie ^a,b   Bellanger, Dorine ^a,b   Vincent Salomon, Anne ^a   Stern, Marc Henri ^a,b  

^a INSTITUT CURIE   (France)

^b INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B;

ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CHROMOSOME 12P; CHROMOSOME DELETION; CONTROLLED STUDY; GENE INACTIVATION; GENE SEQUENCE; HUMAN; HUMAN CELL; LEUKEMOGENESIS; MOUSE; NONHUMAN; NONSENSE MUTATION; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; T CELL LEUKEMIA; TRANSGENICS;

EID: 41349083326     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-06-095570     Document Type: Article

References (40)

1. Stankovic T, Stewart GS, Byrd P, Fegan C, Moss PA, Taylor AM. ATM mutations in sporadic lymphoid tumours. Leuk Lymph. 2002;43:1563-1571.
2. Taylor AMR, Metcalfe JA, Thick J, Mak YF. Leukemia and lymphoma in ataxia telangiectasia. Blood. 1996;87:423-438.
3. Stern MH, Soulier J, Rosenzwajg M, et al. MTCP-1: a novel gene on the human chromosome Xq28 translocated to the T cell receptor alpha/delta locus in mature T cell proliferations. Oncogene. 1993;8:2475-2483.
4. Virgilio L, Narducci MG, Isobe M, et al. Identification of the TCL1 gene involved in T-cell malignancies. Proc Natl Acad Sci U S A. 1994;91:12530-12534.
5. Gritti C, Dastot H, Soulier J, et al. Transgenic mice for MTCP1 develop T-cell prolymphocytic leukemia. Blood. 1998;92:368-373.
6. Virgilio L, Lazzeri C, Bichi R, et al. Deregulated expression of TCL1 causes T cell leukemia in mice. Proc Natl Acad Sci U S A. 1998;95:3885-3889.
7. Joiner M, Le Toriellec E, Despouy G, Stern MH. The MTCP1 oncogene modifies T-cell homeostasis before leukemogenesis in transgenic mice. Leukemia. 2007;21:362-366.
8. Despouy G, Joiner M, Le Toriellec E, Weil R, Stern MH. The TCL1 oncoprotein inhibits activation-induced cell death by impairing PKCθ and ERK pathways. Blood. 2007;110:4406-4416.
9. Stern MH. Clonal T-cell proliferations in ataxia telangiectasia. In: Kirsch IR, ed. The causes and consequences of chromosomal aberrations. Boca Raton, FL: CRC Press; 1993;165-176.
10. Soulier J, Pierron G, Vecchione D, et al. A complex pattern of recurrent chromosomal losses and gains in T-cell prolymphocytic leukemia. Genes Chromosomes Cancer. 2001;31:248-254.
11. Hetet G, Dastot H, Baens M, et al. Recurrent molecular deletion of the 12p13 region, centromeric to ETV6/TEL, in T cell prolymphocytic leukemia. Hematol J. 2000;1:42-47.
12. Santarosa M, Ashworth A. Haploinsufficiency for tumour suppressor genes: when you don't need to go all the way. Biochim Biophys Acta. 2004;1654:105-122.
13. Sherr CJ, Roberts JM. Living with or without cyclins and cyclin-dependent kinases. Genes Dev. 2004;18:2699-2711.
14. Hatta Y, Takeuchi S, Yokota J, Koeffler HP. Ovarian cancer has frequent loss of heterozygosity at chromosome 12p12.3-13.1 (region of TEL and Kip1 loci) and chromosome 12q23-ter: evidence for two new tumour-suppressor genes. Br J Cancer. 1997;75:1256-1262.
15. Kibel AS, Freije D, Isaacs WB, Bova GS. Deletion mapping at 12p12-13 in metastatic prostate cancer. Genes Chromosomes Cancer. 1999;25:270-276.
16. Takeuchi S, Mori N, Koike M, et al. Frequent loss of heterozygosity in region of the KIP1 locus in non-small cell lung cancer: evidence for a new tumor suppressor gene on the short arm of chromosome 12. Cancer Res. 1996;56:738-740.
17. Pietenpol JA, Bohlander SK, Sato Y, et al. Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res. 1995;55:1206-1210.
18. Slingerland J, Pagano M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol. 2000;183:10-17.
19. Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ. The murine gene p27Kip1 is haploinsufficient for tumour suppression. Nature. 1998;396:177-180.
20. Jaffe ES, Harris N, Stein H, Vardiman JW. Tumours of hematopoietic and lymphoid tissues. World Health Organization classification of tumours. Lyon, France: IARC Press; 2001.
21. RTI International. The GDB Human Genome Database. http://www.gdb.org. Accessed June 2004.
22. University of California Santa Cruz. UCSC Genome Browser. http://genome.ucsc.edu/. Accessed October 2007.
23. International HapMap Project. http://www. hapmap.org. Accessed June 2004.
24. Kiyokawa H, Kineman RD, Manova-Todorova KO, et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell. 1996;85:721-732.
25. Probert CS, Williams AM, Stepankova R, Tlaskalova-Hogenova H, Phillips A, Bland PW. The effect of weaning on the clonality of alpha beta T-cell receptor T cells in the intestine of GF and SPF mice. Dev Comp Immunol. 2007;31:606-617.
26. Hoornaert I, Marynen P, Goris J, Sciot R, Baens M. MAPK phosphatase DUSP16/MKP-7, a candidate tumor suppressor for chromosome region 12p12-13, reduces BCR-ABL-induced transformation. Oncogene. 2003;22:7728-7736.
27. Pannetier C, Cochet M, Darche S, Casrouge A, Zoller M, Kourilsky P. The sizes of the CDR3 hypervariable regions of the murine T-cell receptor beta chains vary as a function of the recombined germ-line segments. Proc Natl Acad Sci U S A. 1993;90:4319-4323.
28. Odero MD, Carlson K, Lahortiga I, Calasanz MJ, Rowley JD. Molecular cytogenetic characterization of breakpoints in 19 patients with hematologic malignancies and 12p unbalanced translocations. Cancer Genet Cytogenet. 2003;142:115-119.
29. Sato Y, Suto Y, Pietenpol J, et al. TEL and KIP1 define the sallest region of deletions on 12p13 in hematopoietic malignancies. Blood. 1995;86:1525-1533.
30. Wlodarska I, Mecucci C, Baens M, Marynen P, van den Berghe H. ETV6 gene rearrangements in hematopoietic malignant disorders. Leuk Lymphoma. 1996;23:287-295.
31. Baens M, Wlodarska I, Corveleyn A, Hoornaert I, Hagemeijer A, Marynen P. A physical, transcript, and deletion map of chromosome region 12p12.3 flanked by ETV6 and CDKN1B: hypermethylation of the LRP6 CpG island in two leukemia patients with hemizygous del(12p). Genomics. 1999;56:40-50.
32. Cave H, Cacheux V, Raynaud S, et al. ETV6 is the target of chromosome 12p deletions in t(12; 21) childhood acute lymphocytic leukemia. Leukemia. 1997;11:1459-1464.
33. Morosetti R, Kawamata N, Gombart AF, et al. Alterations of the p27KIP1 gene in non-Hodgkin's lymphomas and adult T-cell leukemia/lymphoma. Blood. 1995;86:1924-1930.
34. Pappa V, Papageorgiou S, Papageorgiou E, et al. A novel p27 gene mutation in a case of unclassified myeloproliferative disorder. Leuk Res. 2005;29:229-231.
35. Spirin KS, Simpson JF, Takeuchi S, Kawamata N, Miller CW, Koeffler HP. p27/Kip1 mutation found in breast cancer. Cancer Res. 1996;56:2400-2404.
36. Pellegata NS, Quintanilla-Martinez L, Siggelkow H, et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci U S A. 2006;103:15558-15563.
37. Knudson A. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971;68:820-823.
38. Muraoka RS, Lenferink AE, Law B, et al. ErbB2/ Neu-induced, cyclin D1-dependent transformation is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells. Mol Cell Biol. 2002;22:2204-2219.
39. Chien WM, Rabin S, Macias E, et al. Genetic mosaics reveal both cell-autonomous and cell-nonautonomous function of murine p27Kip1. Proc Natl Acad Sci U S A. 2006;103:4122-4127.
40. Cayuela JM, Madani A, Sanhes L, Stern MH, Sigaux F. Multiple tumor-suppressor gene 1 inactivation is the most frequent genetic alteration in T-cell acute lymphoblastic leukemia. Blood. 1996;87:2180-2186.